
Contents

Methods and Platforms for the Quantification of Splice

Variants' Expression1

Laurent Bracco, Emeline Throo, Olivier Cochet,

Richard Einstein, Florence Maurier

1	Introduction.....	1
2	General Principles: Specificity is the Key Issue.....	3
3	Low/Medium Throughput Techniques.....	4
3.1	RT-PCR-Based Platforms.....	4
3.1.1	Semi-quantitative RT-PCR	5
3.1.2	Quantitative RT-PCR.....	6
3.2	Alternative Technologies to RT-PCR	8
3.2.1	The Ligase Chain Reaction	8
3.2.2	The RNA-Invasive Cleavage Assay	9
3.3	Conclusion.....	10
4	High-Throughput Analysis of Alternative Splicing Using Microarrays	11
4.1	Introduction	11
4.2	Microarray Configuration and Probe Design	11
4.3	Labeling Protocols.....	15
4.4	Data Analysis	15
4.5	Commercially Available Products	17
4.5.1	Custom Arrays	17
4.5.2	Catalog Arrays	17
4.6	Conclusion.....	18
5	The Detection and Quantification of Splice Variants at the Protein Level.....	18
6	Conclusion	19
	References.....	20

Pre-mRNA Missplicing as a Cause of Human Disease27

Tatyana Novoyatleva, Yesheng Tang, Ilona Rafalska,

Stefan Stamm

1	Importance of Alternative Splicing for Gene Regulation.....	27
1.1	Splice Sites are Selected Through Combinatorial Control	28
2	Human Diseases Caused by Mutation in Splicing Signals	30
2.1	Mutation of Cis-acting Elements.....	30
2.2	Examples of Diseases	31
3	Changes of Trans Factors Associated with Diseases.....	35
4	Human Diseases Associated with Aberrant Splice Site Selection Without Obvious Mutations	36

5	Treatment of Diseases Caused by Missplicing	37
5.1	Gene Transfer Methods	37
5.2	Low Molecular Weight Drugs	38
5.3	Diagnostics	38
6	Conclusions.....	39
	References.....	39

Alternative Splicing: Therapeutic Target and Tool47

Mariano A. Garcia-Blanco

1	Introduction.....	47
1.1	Pre-messenger RNA Splicing and Disease.....	48
2	Conventional Therapies that Have Impact on Splicing	49
3	Oligonucleotide Drugs and Splicing.....	52
3.1	Making Antisense of Splicing.....	53
3.2	Enhanced Antisense.....	55
4	Exon-Specific RNA Interference.....	56
5	RNA-Based Corrective Therapy	56
6	Conclusion	58
	References.....	59

SR Proteins as Potential Targets for Therapy65

Johann Soret, Mathieu Gabut, Jamal Tazi

1	Introduction.....	65
1.1	The Role of SR Proteins in Constitutive and Alternative Splicing	66
1.2	SR Proteins Regulate Alternative Splicing in a Dose-Dependent Way	67
1.3	SR Protein Activity is Regulated by Phosphorylation of Their RS Domain	67
1.4	Involvement of SR Proteins in Human Diseases	68
1.5	Unforeseen Modulation of Alternative Splicing by Various Molecules	69
2	General Modulation of SR Proteins' Expression Level.....	70
2.1	Modulation of Splicing by Histone Deacetylase Inhibitors.....	70
2.2	Modulation of Splicing by Aclarubicin	71
3	General Modulation of SR Proteins' Phosphorylation Level.....	72
3.1	Modulation of Phosphatase Activity.....	72
3.2	Modulation of Kinase Activity	72
4	Modulation of Specific SR Proteins' Expression Level.....	75
4.1	Overexpression of SR Proteins	75
4.2	Down-Regulation of SR Proteins' Expression.....	76
5	Selective Modulation of SR Proteins' Activity.....	77
6	Concluding Remarks.....	78
	References.....	79

Misregulation of Tau Alternative Splicing in Neurodegeneration and Dementia89

Athena Andreadis

1	Brief Overview of Constitutive and Alternative Splicing	89
2	Structure, Transcripts, and Alternative Splicing of the Tau Gene	90
3	Tau Splicing and Neurodegeneration, Prologue	93
4	Commonalities in the Splicing Regulation of Tau Exons 2 and 10.....	95
4.1	Exon 2 – Splicing Regulation and the Possible Connection to DM 1	95
4.2	Exon 10 – Splicing Regulation and the Established Connection to Tauopathies.....	97
5	Tau Connection to Disease, Epilogue.....	100
	References.....	102

Spinal Muscular Atrophy and Therapeutic Prospects109

Brunhilde Wirth, Lars Brichta, Eric Hahnen

1	Clinical Picture of Spinal Muscular Atrophy (SMA)	109
2	Molecular Basis of SMA	110
2.1	SMN, the SMA Determining Gene	111
2.2	Alternative Splicing of SMN Transcripts.....	112
2.2.1	Splicing Regulation of SMN Exon 7	112
2.3	The SMN Protein Function.....	116
2.4	SMN1 Gene Mutations in SMA Patients	117
2.5	Influence of SMN2 Copy Number on the SMA Phenotype	117
2.6	Evidence for Further Genes Modifying the Disease Severity	118
3	Therapeutic Prospects for SMA	119
3.1	Drugs that Increase the SMN Protein Level	119
3.1.1	Histone Deacetylase (HDAC) Inhibitors that Increase the SMN-RNA/Protein	120
3.2	Correction of Exon Skipping by Synthetic Small Molecules.....	122
3.3	A First Causal Therapy for SMA Patients?	122
4	Conclusions and Perspectives	123
	References.....	124

Misregulation of Alternative Splicing Causes Pathogenesis in Myotonic Dystrophy133

N. Muge Kuyumcu-Martinez, Thomas A. Cooper

1	Myotonic Dystrophy	133
2	Repeat Instability	134
3	Mechanism of DM Pathogenesis	135

3.1	Loss of Function of DMPK.....	136
3.2	Loss of Function of Surrounding Genes.....	137
3.3	RNA "Gain of Function" Hypothesis.....	137
3.3.1	Misregulation of Alternative Splicing.....	138
3.4	Mechanisms of Misregulated Alternative Splicing.....	142
3.4.1	Increased CUG-BP1 Splicing Activity.....	143
3.4.2	Sequestration of MBNL Proteins.....	144
3.4.3	Sequestration of Other RNA Binding Proteins.....	147
3.4.4	Transcriptional Interference.....	147
3.4.5	Muscle Differentiation Defects and Altered Translation Regulation.....	148
	References.....	149

Redirecting Splicing to Address Dystrophin Mutations:

Molecular By-pass Surgery161

Stephen D. Wilton, Susan Fletcher

1	The Dystrophin Gene and Duchenne Muscular Dystrophy.....	161
1.1	The Dystrophin Gene and Products.....	161
1.2	Duchenne and Becker Muscular Dystrophy.....	164
1.3	Dystrophin Mutations.....	165
1.4	Atypical Mutations: Exceptions to the Reading Frame Hypothesis.....	169
1.5	Revertant Fibres.....	170
2	Splicing.....	171
2.1	Mechanism of Pre-mRNA Processing.....	171
2.2	Alternative Splicing.....	172
2.3	Antisense Oligonucleotide Modification of Splicing Patterns.....	174
2.4	Antisense Oligonucleotide Chemistries.....	175
2.5	Candidate Genes for Splicing Intervention.....	175
3	Molecular By-pass Surgery for Duchenne Muscular Dystrophy.....	176
3.1	The Dystrophin Gene and Redirected Splicing.....	176
3.2	Antisense Studies in Animal Models of Muscular Dystrophy.....	179
3.3	Human Dystrophin Gene Studies.....	181
3.4	Antisense Oligonucleotide Delivery.....	184
4	Clinical trials.....	185
4.1	Fine-Mapping Dystrophin Mutations.....	186
4.2	Trial Design.....	186
5	The Future.....	188
	References.....	189

Altered Splicing in Prelamin A-Associated Premature Aging Phenotypes.....	199
Annachiara De Sandre-Giovannoli, Nicolas Lévy	
1 Altered Lamin A/C Function and Disease: the “Laminopathies”	199
1.1 <i>LMNA</i> -Encoding Lamins A/C, Fundamental Nuclear “Bricks”	200
1.1.1 Involvement in Nuclear Structure, Morphology, and Resistance to Stress	203
1.1.2 Regulation of Gene Expression.....	203
1.2 The “Laminopathies”	204
2 Altered Lamin A Splicing and Progeroid Syndromes.....	209
2.1 Hutchinson-Gilford Progeria Syndrome	210
2.2 Restrictive Dermopathy	215
2.2.1 Lamin-Linked RD.....	215
2.2.2 <i>ZMPSTE24</i> -Linked RD	217
3 Hypothetical Pathophysiological Mechanisms Involved in Laminopathies and Progeroid Syndromes Linked to <i>LMNA</i> and <i>ZMPSTE24</i> in Relation to Animal Models Possible Therapeutic Strategies	218
4 Conclusions and Future Prospects	221
References.....	223
Splicing Modulation as a Modifier of the CFTR Function.....	233
Malka Nissim-Rafinia, Batsheva Kerem	
1 The CF Disease and the CFTR Gene	233
2 Spectrum of Splicing Mutations in the CFTR Gene.....	234
2.1 Splicing Mutations Leading to Complete Aberrant Splicing.....	234
2.2 Splicing Mutations Leading to Partial Generation of Correct Splicing	235
2.2.1 The 3849+10 kb C→T Mutation	235
2.2.2 The 2789+5 G→A Mutation	237
2.2.3 The 3272–26 A→G Mutation.....	237
2.2.4 The IVS8–5T Allele.....	237
2.3 Exonic Point Mutations Leading to Aberrant Splicing	238
3 Correlation Between Levels of Correctly Spliced RNA and Disease Severity	239
4 Splicing Modulation by Splicing Factors	241
4.1 Splicing Modulation of CFTR Minigenes Carrying Splicing Mutations.....	241

4.1.1	The 3849+10 kb C→T Minigene	242
4.1.2	The IVS8-5T Minigene	242
4.1.3	Exon 9 Minigene Carrying the A455E Mutation	243
4.1.4	Exon 12 Minigenes Carrying the D565G and G576A Mutations	244
4.1.5	Exon 13 Minigenes	244
4.2	Splicing Modulation of Endogenous CFTR Allele Carrying 3849+10 Kb C→T Splicing Mutations and Restoration of the CFTR Function	245
5	Splicing Modulation by Small Molecules	248
6	Splicing Modulation by Antisense Oligonucleotides	249
	References	250
	Index	255